Literature DB >> 3530904

gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant.

M C Roncaglioni, A P Dalessandro, B Casali, C Vermeer, M B Donati.   

Abstract

Rabbit V2 carcinoma tissues have been described to possess a procoagulant activity with specific characteristics; this material has been purified and identified as a cysteine proteinase able to directly activate coagulation factor X. We have shown here that the procoagulant activity of V2 carcinoma extracts is depressed in warfarin-treated animals, thus suggesting that cancer procoagulant could represent a new vitamin K-dependent protein. The biochemical basis for this effect is offered by the identification of gamma-glutamyl carboxylase in the microsomal fraction of tumor tissues. The V2 carcinoma has a carboxylase activity which is increased in warfarin-treated animals. An endogenous substrate of tumor carboxylase, the nature of which has not been identified, has been found 5-fold increased in warfarin-treated animals. The presence of gamma-glutamyl carboxylase was also described in several murine tumors including both carcinomas and fibrosarcomas. It is worth mentioning that all the tumors tested produce a procoagulant with the peculiar characteristics of that described in V2 carcinoma. It is conceivable that cancer procoagulant could represent at least one of the substrates for gamma-glutamyl carboxylase in these experimental tumor tissues.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530904     DOI: 10.1159/000215301

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  2 in total

1.  Tissue procoagulant activity may be important in sustaining metastatic tumour growth.

Authors:  N J Carty; I Taylor; O S Roath; K el-Baruni; J L Francis
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

2.  The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding.

Authors:  J L Francis; N Carty; M Amirkhosravi; M Loizidou; A Cooper; I Taylor
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.